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Abstract: Drugs targeting heat shock protein 90 (Hsp90) have been extensively explored for their
anticancer potential in advanced clinical trials. Nanoformulations have been an important drug
delivery platform for the anticancer molecules like Hsp90 inhibitors. It has been reported that bovine
serum albumin (BSA) nanoparticles (NPs) serve as carriers for anticancer drugs, which have been
extensively explored for their therapeutic efficacy against cancers. Luminespib (also known as
NVP-AUY922) is a new generation Hsp90 inhibitor that was introduced recently. It is one of the most
studied Hsp90 inhibitors for a variety of cancers in Phase I and II clinical trials and is similar to its
predecessors such as the ansamycin class of molecules. To our knowledge, nanoformulations for
luminespib remain unexplored for their anticancer potential. In the present study, we developed
aqueous dispensable BSA NPs for controlled delivery of luminespib. The luminespib-loaded BSA NPs
were characterized by SEM, TEM, FTIR, XPS, UV-visible spectroscopy and fluorescence spectroscopy.
The results suggest that luminespib interacts by non-covalent reversible interactions with BSA to
form drug-loaded BSA NPs (DNPs). Our in vitro evaluations suggest that DNP-based aqueous
nanoformulations can be used in both pancreatic (MIA PaCa-2) and breast (MCF-7) cancer therapy.
Keywords: BSA nanoparticles; Hsp90; luminespib (NVP-AUY922); pancreatic cancer; breast cancer
1. Introduction
The development of drugs against breast and pancreatic cancer is a major challenge due to
various back channels, such as drug efflux mechanism by p-glycoproteins (p-gp), development of drug
resistance to human epidermal growth factor 2 (HER2) targeted therapy and overexpression of heat
shock proteins (HSPs). Newer strategies such as mono or combination therapies that target multiple
cellular pathways of cancer cells are being developed to fight against these complexities of breast and
pancreatic cancer [1–3]. Studies suggests that development of drug-targeting HSPs is one of the most
promising ways to fight a variety of cancers [4].
The microenvironment of cancer cells is extremely stressful due to acidic pH, oxidative stress,
nutritional stress, phototoxic stress, hypoxic and other stress conditions. This turbulent cellular
microenvironment serves as a hallmark for cancer. It has been shown that heat shock protein 90 (Hsp90)
is overexpressed in cancer cells in order to buffer such stressful conditions and provide cyto-protective
function to them [4–6]. Hsp90 is an important molecular chaperone, which has thousands of client
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proteins that play an important roles in the growth promotion and the survival of cancer cells under
stress conditions [7]. Hence, Hsp90 works as a central hub for survival of cancer cells by interacting
with a large number of unfolded or damaged essential proteins and helps in their folding by forming a
multichaperone complex. As a result, inhibition of Hsp90 can hinder a large number of essential cellular
pathways for cancer cells, which ultimately leads to cell death. An ansamycin analog-17-allylamino
17-demethoxygeldanamycin (17AAG)—was the first Hsp90 inhibitor that entered clinical trial against
cancer by Bristol Myers Squibb. There are around fifteen molecules that have been explored as single
or combination therapies. Most Hsp90 inhibitors acts by binding to the N-terminal domain that causes
inhibition of the protein-folding pathway followed by activation of proteasomal degradation of client
protein [8].
Being one of the most promising cancer drug targets, Hsp90 inhibitors were explored for their
efficacy against breast cancer therapy. It was reported that 17AAG proved to be effective in a phase II
trial for HER2 +ve breast cancer therapy [9]. Other Hsp90 inhibitors, like 17-Dimethylaminoethylamino-
17-demethoxygeldanamycin (17DMAG), 17-Allylamino-17- Demethoxygeldanamycin Hydroquinone
Hydrochloride (IPI-504), have also shown promising results towards breast cancer, pancreatic cancer
and various forms of cancer treatment in single or combination therapy. This indicates that Hsp90
inhibitors can be effective therapeutic molecules against multiple cancer types. Various parent structures
like resorcinol, purine analogs and others are being pursued in order to identify newer derivatives as
anticancer molecules, which offers improved binding affinities towards Hsp90 proteins and are effective
against various phenotypes of cancers compared to first generation ansamycin analogs [10,11].
Luminespib was recently introduced in the quest for finding a newer potent Hsp90 inhibitor. It is
an iso-oxazole resorcinol-based synthetic Hsp90 inhibitor (as shown in Figure 1a) that was discovered
with an intention to develop newer and better anticancer molecules [12]. It is was explored for its
broad-spectrum anticancer activity in >10 clinical trials (clinicaltrials.gov), including estrogen receptor
(ER) +ve and herceptine (HER) +ve breast cancer conditions [13,14]. The molecule was also found to
be effective towards pancreatic cancer (MIA PaCa-2) cell line [15]. Hence, we believe that this single
molecule may be useful for chemotherapy in multiple cancer types. Although it is a clinically explored
experimental new drug molecule, luminespib remains unexplored for developing controlled delivery
nanoformulations. The only formulation used for luminespib in a preclinical breast cancer model was
in 60-mM lactic acid or 2.5% ethanol, 20% 50-mM tartaric acid and 77% (5% glucose in water containing
1% Tween-80) vol/vol [12,16]. Infusion of the complex formulation comprising ethanol, tartaric acid
and lactic acid may lead to dose dependent toxicity. The molecule was explored in early Phase I and
Phase II clinical trials against breast cancer, non-small cell lung cancer, refractory multiple myeloma,
advanced solid tumors and others [17–19]. We believe that the development of water dispensable
nanoformulations of luminespib should help to increase patient compliance.
A number of polymeric and nonpolymeric nanocarriers have been extensively explored for
their potential drug formulation applications [20,21]. Polymeric nanoformulations have played an
important role in developing successful nanoparticle (NP)-based anticancer therapy [7]. Polymeric
nanoformulations have been used in developing novel aqueous formulation for hydrophobic Hsp90
inhibitors like 17AAG. Our lab had developed hydrophilic polymeric nanoformulations as 2-in-1
iron oxide (MNP) and 17AAG-loaded polymeric nanoformulation with the aim of combining the
cytotoxicity property of 17AAG with magnetic hyperthermia in the same formulation [22]. Recently,
there is a constant demand in the ideas of using various biopolymers to make better nanoformulations.
Protein-based carriers such as serum albumin have shown an intriguing potential to be utilized
in nanoformulation [23,24]. Serum albumin is one of the most abundant proteins in the circulating
system of a wide variety of organisms. The two most common types of albumin that are used in
biomedical applications; (a) bovine serum albumin (BSA) and (b) human serum albumin (HSA). BSA
shares nearly 76% sequence homology with HSA [25]. Hence, BSA is the most commonly used model
protein for drug interaction studies and nanodrug delivery vehicle. Serum albumin is a major molecule
in the plasma of animals, and it accounts for nearly 60% of total protein (with a concentration of 42 g
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dm−3). It consists of a single chain of 582 amino acids divided into three linearly arranged domains
(I–III) [26]. The interaction of anticancer drugs with BSA has been extensively explored for developing
novel formulations. Nab-paclitaxel (Abraxane) is the first albumin-stabilized nanoformulation to be
approved by Food and Drug Administration (FDA) in 2005 for its efficacy in the treatment of breast
cancer [27]. It was also approved by FDA for metastatic pancreatic cancer and non-small cell lung
cancer. BSA–dextran–folic acid–doxorubicin nanoconjugate also showed efficacy in murine ascites
hepatoma H22 tumor-bearing mice [28]. Furthermore, gemcitabine and folate gemcitabine-loaded
nanoconjugates showed efficacy against pancreatic and MCF-7 breast cancer cell lines [29]. Albumin
nanocarriers for 17AAG were also explored. It was found that nab-17AAG with an average size of
210 nm was shown to have considerable anticancer activity towards MX-1 breast cancer cell line [30].
The study provided positive evidence that the nab formulation of Hsp90 inhibitor could improve its
efficacy, safety and stability in comparison to their surfactant and solvent-based formulations [30].
Based on the success of earlier studies, we have explored the possibility to develop BSA nanoparticles
consisting of luminespib and investigated its biocompatibility and efficacy towards MCF-7 and MIA
PaCa-2 cell lines.
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Figure 1. (a,b) Structure of luminespib and bovine serum albumin (BSA) (protein databank (PDB):
3V03), respectively; (c) schematics of synthesis and anticancer efficacy of drug-loaded BSA nanoparticles
(NPs) towards cancer cell lines in comparison to native or blank BSA NPs.
2. Materials and M thods
BSA was obtained from Sigma-Aldrich (Tokyo, Japan), ethanol (99%) was procured from Wako
(Tokyo, Japan); luminespib was pur ha ed fro LC laboratories (Woburn, MA, USA). Thin-layer
chromatography (TLC) plates were obtained from Merck Millipore (Burlington, MA, USA). Trypan
blue, trypsin EDTA (0.025%), alamar blue cytotoxicity kit and Dulbecco’s modified Eagle’s medium
(DMEM) were procured from Invitrogen (Tokyo, Japan).
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2.1. Synthesis of BSA-Luminespib Nanoconjugates
The synthesis of luminespib (drug) BSA nanoconjugates was achieved using desolvation
method [31,32]. BSA protein (100 mg) was dissolved in distilled water and the pH was adjusted to
around 8.0. The basic pH adjustments were performed using 0.1-M NaOH. To 10 mg of luminespib,
2 mL of absolute ethanol was added to dissolve the drug, and the (ethanolic-drug) solution was
dropwise added to BSA (0.5 mL) solution at the rate of 0.5 mL/min using a syringe pump. Slow
addition of drug containing ethanol solution causes formation of white suspension that indicates
formation of drug–BSA conjugates. Native BSA NPs were prepared by controlled addition of ethanol
to BSA solution. These drug–BSA NPs and native BSA NPs were subjected to crosslinking with 8%
glutaraldehyde solution at room temperature for 4 to 5 h. The cross-linked drug-BSA nanoconjugates
were subjected to washing with distilled water and centrifuged at 15,000 rpm. The collected pellet was
freeze-dried and reconstituted in phosphate buffer saline (7.4 pH, PBS) for further studies.
2.2. Luminespib BSA Particle Characterization Studies
Specific quantity of BSA-drug nanoconjugates was filtered and analyzed for particle size, zeta
potential and poly-dispersity index determination using Malvern NanoZS analyzer. The data were
recorded using Zetasizer (version 2.0, Malvern Panalytical, Tokyo, Japan). All the experiments were
performed in triplicates and the data were expressed as standard deviation. Surface morphology
characteristics of nanoparticles were determined using scanning electron (SEM) and Transmission
electron microscopy (TEM). For SEM, the sample was dropped on glass substrate, vacuum dried and
coated with platinum for taking images using SEM 6600 (Hitachi, Tokyo, Japan). DNP sample was
dropped on TEM hydrophilic copper grid and images were taken using JEM-2100 (Jeol, Tokyo, Japan),
at 160 kV.
2.3. In Silico Molecular Docking
Docking calculations were carried out using Docking Server [33]. The crystal structure of BSA
was downloaded from protein databank (PDB), accession number 3V03. The structure of the ligand
(luminespib) with PubChem ID 135539077 was taken for carrying out the docking simulations. PM-6
partial calculations method was used for both ligand and protein. Further, the geometry for ligand was
performed using MMFF94. Nonpolar hydrogen atoms were merged, and rotatable bonds were defined.
Essential hydrogen atoms, Kollman united atom type charges, and solvation parameters were added
with the help of AutoDock tools [34]. Affinity (grid) maps of 90 × 60 × 80 Å grid points and 0.375 Å
spacing were generated using the Autogrid program (Virtua Drug, Budapest, Hungary and Scripps
Research Institute, La Jolla, CA, USA). AutoDock parameter set and distance-dependent dielectric
functions were used in the calculation of the van der Waals and the electrostatic terms, respectively.
Docking simulations were performed using the Lamarckian genetic algorithm (LGA) and the
Solis & Wets local search method used by DockingServer GUI [35]. Initial position, orientation and
torsions of the ligand molecules were set randomly. All rotatable torsions were released during
docking. Each docking experiment was derived from 100 different runs that were set to terminate after
a maximum of 2,500,000 energy evaluations. The population size was set to 150. During the search,
a translational step of 0.2 Å, and quaternion and torsion steps of 5 were applied.
For analysis, docking results were ranked based on free energy of binding (kcal/mol), number of
hydrogen bonds, polar interactions and frequency of probable binding sites. The frequency shows the
percentage of the local searches with similar geometry having root mean square tolerance (rmstol)
of 2 Å. The docked structures with lowest binding free energy, with maximum number of polar and
hydrogen bond interactions, and with frequency of 10% or more were used for prediction of probable
binding configuration. The analyzed docking file in.pdb format was downloaded and analyzed using
Discovery Studio Visualizer 4.0 (Biovia, Tokyo, Japan).
Polymers 2020, 12, 1798 5 of 17
2.4. Luminespib-BSA Interaction Studies
2.4.1. Fluorescence Quenching Studies for Drug BSA Complex
Fluorescence spectroscopy measurements were carried out for a fixed concentration of BSA 12.5µM.
The drug concentration was varied from 0.0 to 12.5 µM at room temperature. Various concentrations
of drug were made in 30% ethanolic PBS solution at pH 7.4. Fluorescence spectra were measured
using FP6500 (Jasco, Tokyo, Japan), Jasco instrument. The excitation were kept as 280 nm. Further,
at the same instrument settings we also checked the quench in fluorescence spectra for BSA–drug
nanoconjugates in comparison to native BSA particle in PBS (pH 7.4) at 1 mg/mL concentration.
2.4.2. UV-Vis Absorption Studies
To determine the presence of drug in the BSA NPs; we performed UV-vis. absorption studies
for 1 mg/mL concentration of drug–BSA conjugates (DNPs) dispersion in PBS (pH 7.4). Here, the UV
spectrum was also recorded for the plain BSA nanoparticle and free drug as control.
2.4.3. Thin-Layer Chromatography (TLC)
To understand the drug interaction with BSA and formation of nab-luminespib nanoformulations,
we performed TLC measurements. We spotted 10 µL of 1 mg/mL concentration of DNPs in deionized
water on TLC plates and compared them to blank BSA NPs and native drug as controls. We used
chloroform, methanol and concentrated NH4OH (80:20:1) as mobile phase. Rf value was calculated for
spots after checking TLC plates under UV illumination.
2.4.4. X-ray Photoelectron Spectroscopy Studies (XPS)
XPS measurement was performed using Phi Quantes XPS system (Ulvac-Phi, Kanagawa, Japan).
Samples were mounted on glass slide and subjected to recording for individual spectral recordings for
carbon, nitrogen, oxygen and wide scan. All the measurements were made using aluminum X-ray at
55-pass energy. The XPS data were analyzed using Multipack software (Ulvac-Phi, Kanagawa, Japan).
2.5. Encapsulation and Drug Loading Evaluation
In our study, 1 mg of BSA-drug nanoconjugates was taken and dispersed in 1 mL of ethanol and
subjected to quantitation of luminespib at 310 nm (DU® 730 UV Spectrometer by Beckman Coulter,
Tokyo, Japan). Drug encapsulation and drug-loading efficiency studies were performed in triplicates
using the following Equations (1) and (2):
Encapsulation e f f iciency (%) =
Amount o f Luminespib in nanoparticles
Total weight o f Luminespib used f or synthesis
× 100 (1)
Drug loading e f f iciency (%) =
Amount o f Luminespib in nanoparticles
Gross weight o f nanoparticles
× 100 (2)
2.6. Stability of DNPs
To study the stability of DNPs at ambient room temperature, nanoparticles were stored at
25 ◦C in glass vial. Samples were drawn to check the stability of formulation for up to seven
days. Here, the particle size distribution and SEM image were used as quantitative and qualitative
checkpoints, respectively.
2.7. In Vitro Drug Release for DNPs
In our study, 20 mg of nanoparticles were taken and dispersed in 20 mL of deionized water.
The solutions were distributed in Eppendorf tubes such that each tube consisted of 1 mg/mL
concentration. All the tubes were kept in a shaking incubator at 37 ◦C. At predetermined time
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intervals supernatant was taken and subjected to UV absorbance reading at 310 nm for determination
of quantity of drug released. All the measurements were performed in triplicates and data were plotted
as an average of the drug released at specific time points.
2.8. Cell Culture and In Vitro Cytotoxicity Studies
To check the cytotoxicity, we carried out culturing of MCF-7 and MIA PaCa-2 cancer cell lines.
We also cultured normal mouse fibroblast cell line (L929) as control. MCF-7 and L929 cell lines were
cultured in DMEM media consisting of 10% FBS and 5% penicillin/streptomycin (100 units per mL).
MIA PaCa-2 was cultured in RPMI media with 10% FBS and 5% penicillin/streptomycin (100 units per
mL). All the cells were incubated at 37 ◦C in a humidified CO2 environment. The confluent T-25 plates
were sub cultured every third day.
MCF-7, MIA PaCa-2 and L929 cells were seeded in 96-well plates with a cell density of 5000 cells
per well and cytotoxicity assay was performed with the synthesized nanoformulations using alamar
blue dye. After 24 h of incubation in 96-well plates, cell lines were treated with DNPs in concentration
dependent manner from 100 to 1000 µg/mL. The treated plates were subjected to measurement of
fluorescence at excitation and emission wavelength as 580 and 530 nm, respectively. The measurements
were made using Power scan HT, Micro plate reader, Dainippon Sumitomo Pharma, Osaka, Japan.
The cell viability measurements were made for 48 h. We used Equation (3) for measurement of%
cell viability. All the experiments were performed in triplicates and subjected to Student’s t-test for
statistical significance.




3. Results and Discussion
3.1. Synthesis, Particle Size Characterization and Encapsulation of BSA Luminespib NPs
Synthesis of DNPs was carried out using a desolvation method wherein ethanol acts as an
anti-solvent as shown in Figure 1c [32,36]. Our dynamic light scattering (DLS) studies showed that the
average particle size of DNPs was around 222.43 ± 1.150 nm as shown in Table 1 and Figure 2a. The
zeta potential of the nanoformulation was found to be −30.63 ± 1.365 mV with a poly dispersity index
of 0.133 ± 0.014 as shown in Figure 2b and Table 1, respectively. We believe that low poly dispersity
and particle size of around 222 nm may be attributed to the ethanol as desolvating agent and pH 8 used
during the synthesis of the nanoparticles [37,38]. Moreover, our synthesized nanoformulation shows
similar DLS and particle size distribution characteristics as shown in previously reported cases of BSA
NPs [32]. The particle size and spherical morphology of the synthesized DNPs were also confirmed by
SEM and TEM as shown in Figure 2c,d. Further, the drug entrapment studies show that the DNPs
has encapsulation efficiency of 48.22 ± 1.948% and drug-loading of 4.28 ± 1.94 [39]. To evaluate and
confirm the probable drug–protein interaction mechanism we performed molecular simulations and
fluorescent quenching studies.
Table 1. Physical-chemical characterization of drug-loaded BSA NPs (DNPs).
Parameters Values
Z-average particle size (nm) 222.433 ± 1.150
Zeta potential average (mV) −30.63 ± 1.365
Poly dispersity index (PDI) 0.133 ± 0.014
Encapsulation efficiency (%) 48.22 ± 1.948
Drug loading 4.28 ± 1.94
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Figure 2. (a,b) Particle size distribution between 78 to 500 nm and zeta-potential distribution of −11.8
to −48.1 mV. The average particle size (obtained from DLS) was found to be around 222 nm and average
zeta potential as around −30 mV; (c,d) SEM and TEM images of the synthesized DNPs, respectively.
SEM images shows particle various sizes around ~200 nm. TEM images confirms small particle size
~100 to 150 nm. The DNP images from SEM and TEM confirmed the observation from DLS.
3.2. BSA Luminespib Interaction Studies
Synthesis of BSA luminespib NPs depends on the interaction of luminespib with BSA at the
structural level. To evaluate this as a first step, we performed luminespib docking studies to find
the probable binding site. Our result indicates that Gibbs free energy of drug binding to BSA was
−10.48 kcal/mol with frequency of 50% and predicted inhibition (Ki) as 20.64 M as shown in Figure 3a.
The del s ows that luminespib may form relatively more stable drug-BSA complex compared to
previously reported cases of drug-BSA interaction due to rel tively low binding fr e energy found
in the range of −4.35 to −5.45 kcal/mol [32,40]. We also observed that the ru int racts with nearly
fou teen interaction residues with mainly three important typ s of interactions such as H-bonds, po ar
and hydrophobic i teractions. Our model indicates that the probable binding pocket of luminespib
shows three hydrogen bond interactions, five p lar and six hydrophobic interactions with BSA residues
(as shown in Table 2). From the d cking simulation, we believe that the probable binding site for
the luminespib is ydrophilic domain I of BSA, Figure 3a. The stable hydrog n bond interaction
between amino acid res dues such as Tyr 147, Ser 428 and Ser 192 and luminespib is shown in Figure 3b.
This may be due to the anion c nature of l minespib that helps in forming hydrogen bond nteractions.
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In addition, it also has amine-containing heterocyclic functional group to stabilize the protein-ligand
complex via. hydrogen bond interactions as seen with other pharmacophores [41,42].
Polymers 2020, 12, x FOR PEER REVIEW 8 of 17 
 
the protein-ligand complex via. hydrogen bond interactions as seen with other pharmacophores 
[41,42]. 
 
Figure 3. (a) Binding pocket for luminespib in BSA; (b) amino acid residues of BSA that interact with 
luminespib through hydrogen bond interactions. It also shows the interaction bonding distance for 
the hydrogen bonds when BSA protein interacts with luminespib. 
Table 2. The amino acid residues of BSA (PDI: 3V03) that interacts with luminespib to form a stable 
protein-ligand complex. 




























   
 
ASP108 
(−0.479)    
In order to confirm that the drug interacts with the BSA, we performed fluorescence quenching 
experiment. Here, we kept the concentration of BSA as a constant (12.5 µM) and stepwise increased 
the concentration of luminespib solution (3.125 µM to 12.5 µM). We observed a great drop or 
quenching in the fluorescent intensity with the increase in the drug concentration as shown in Figure 
4a. This indicates that the drug interacts with BSA, and quenching is attributed to the changes in the 
BSA microenvironment due to the drug interaction [43]. We also recorded the fluorescence spectra 
for native BSA NPs and compared it to that of DNPs at a concentration of 1 mg/mL. It was observed 
a nearly 8-fold difference as shown in Figure 4c. The decrease in the relative fluorescence intensity 
for DNPs can be attributed to the formation of drug-BSA complex [32]. The presence of the drug-BSA 
complex was also confirmed from the UV absorption peaks as shown in Figure 4b. The drug signal 
at around 310 nm in DNPs that coincides with pure drug signal as positive control was observed. The 
signal was absent in native BSA NPs. Overall, UV and fluorescence spectroscopy confirms the 
ig re 3. ( ) i i t f l i i i ; ( ) i ci resi es f S t at interact ith
l inespib through hydrogen bond interactions. It also shows the interaction bondi g distance for the
hydrogen bo ds when BSA protein interacts with luminespib.
Table 2. The amino acid residues of BSA (PDI: 3V03) that interacts with luminespib to form a stable
protein-ligand complex.





























In order to confirm that the drug interacts with the BSA, we performed fluorescence quenching
experiment. Here, we kept the concentration of BSA as a constant (12.5 µM) and stepwise increased the
concentration of luminespib solution (3.125 µM to 12.5 µM). We observed a great drop or quenching
in the fluorescent intensity with the increase in the drug concentration as shown in Figure 4a.
This indicates that the drug interacts with BSA, and quenching is attributed to the changes in the BSA
microenvironment due to the drug interaction [43]. We also recorded the fluorescence spectra for
native BSA NPs and compared it to that of DNPs at a concentration of 1 mg/mL. It was observed a
nearly 8-fold difference as shown in Figure 4c. The decrease in the relative fluorescence intensity for
DNPs can be attributed to the formation of drug-BSA complex [32]. The presence of the drug-BSA
co plex as also confir ed fro the UV absorption peaks as sho n in Figure 4b. The drug signal
at around 310 n in DNPs that coincides with pure drug signal as positive control was observed.
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The signal was absent in native BSA NPs. Overall, UV and fluorescence spectroscopy confirms the
interaction between ligand and protein. Luminespib probably interacts with BSA through various
non-covalent forms of interactions (indicated in Table 2) for the formation of self-assembled DNPs.
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Figure 4. (a) Fluorescence quenching when BSA interacts with luminespib while formation of drug
BSA nanoconjugates; (b) DNPs when subjected to UV absorptions studies, it shows presence of a
peak around 310 nm, the same as that of the native drug and blank BSA NPs as controls; (c) DNP
nanodispersion in PBS 7.4 pH at 1 mg/mL concentration was studied with fluorescence spectroscopy
where native BSA NPs were taken as control.
3.3. X-ray Photo Electron Spectroscopy, TLC and Stability Studies
Further, to confir the presence of the drug interaction with BSA we perfor ed XPS analysis. It
can be see 1a that the drug consi t of nitrogen- and oxygen- containing heterocyclic ring
struc ure. H nce, th presence of these ring systems in DNP conjugates m y provide elative shifts or
changes in the atomic signals for c rbon and nitrogen due to the electron-withdra ing and donating
microenvironment of DNPs in compar son to n tive BSA NPs. Figure 5a hows the compari on of
carbon ignatures from DNPs, native BSA NPs and drug. It w s observed that –N–C=O bond peak
was observed at 286.45 fo BSA, which was shifted to 287 (shifted by 1.05 eV) for DNPs. This positive
shift may be attributed to the presence of electron withdrawing a mat c nucleus of the drug present
in DNPs. Further, we also observed three-peak signatures for DNPs and dr g sample that was absent
in native BSA NPs as shown in Figure 5a. In this three-peak sign ture, the peak at 285 eV (Figure 5a)
is correspondent to –C=N bond, which corresponds to the –C=N– f iso- xazole moiety of the drug
molecule (Figure 1a) [44].
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These observations clearly show the presence of drug in DNPs in comparison to positive (native 
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Figure 5. XPS spectra for carbon 1s (C 1s) and nitrogen 1s (N 1s) alterations in binding energy peaks
for DNPs in comparison to native BSA NP and luminespib as control. (a) C 1s shifts also mark the
presence of peak at second position for drug and DNPs whereas its absence in native BSA NPs; (b) N
1s peak shifts and the presence of peak at position one for drug and DNPs whereas its absence in native
BSA NPs. Peak fitting function by multipack software, helps in identification of multiple peaks in
the raw data. The sharp solid lines in above spectra represents peak fits for identification of single or
multiple peaks in the wavy lines of raw data.
Moreover, to understand the nature of changes in carbon signals, we an lyzed the r lative changes
in th nitrogen signatures. It was observed that XPS peak for =N–O– was absent in native BSA, but it
was present in drug and DNP spect as shown in Figure 5b. The =N–O– pe k was found to be slightly
shifted to 401.3 for DNPs than native drug where it was fo nd to be at 399.75 eV [45]. These results
also suggest the drug-protein interactions, which is consistent with the fluore cence and UV.
Furthermore, to confirm the presence of drug in DNP na oconjugates, we performed TLC studies
in comparison to native drug an BSA NPs as shown in Fig re 6. It wa observed that 10 µL spot
of DNP at 1 mg/mL concentration in deionized water provided an average Rf value of 0.64 ± 0.03.
However, ethanol solution of native drug gave Rf value of 0.85 ± 0.005 (as shown in Figure 6).
These observations clearly show the presence of drug in DNPs in comparison to positive (native drug)
and negative (BSA NPs) control [31]. The difference in the Rf values for the native drug and DNPs is
due to the interaction of drug with BSA in DNP formulation. This result also supported our previous
experimental results provided by fluorescence and UV spectroscopy.
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3.4. In Vitro Drug Release Studies 
The drug release studies of DNP formulation were performed under pH 7.4 for 72 h. It was 
observed that the first burst release of the drug occurred in the first 8 h of incubation period. It can 
be seen that there was a time-dependent exponential increase in the drug release for 24 h. This was 
Figure 6. Thin-layer chromatography (TLC) image with the 10 µL spot of DNPs in comparison to
native BSA NPs and luminespib on TLC plate as controls. The solvent front was run for 144 cm to
calculate Rf values for respective mobility of spots for BSA NPs, DNPs and native drug. Our results
show a real time shifts in the spot position for luminespib from DNPs in comparison to native drug.
The calculated Rf values were performed n = 3 times and average were taken to determine the shift in
the position of spots.
It was also important to check the stability of the formulation to understand the storage condition
of the formulation. Most nanoparticles preparations can be stored under room temperature [46,47].
To assess this, we performed stability evaluation for our preparation. As shown in Figure 7a,b. There
was insignificant increase in the particle size from 220 nm (Day 0) to 255 nm (Day 7) and polydispersity
index from 0.133 (Day 0) to 0.176 (Day 7). Further, we also observed that there was relative increase
in number of particles in the size range of around 500 to 700 nm. This could be due to the polymer
swelling over time or due to particle aggregations. To check the visual observation, SEM was performed.
Overall, data from particle size distribution and SEM suggests that the nanoparticles are stable at room
temperature for nearly 7 days, but may aggregated over time at 25 ◦C. Hence, dispersions require
necessary sonication before use.
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Figure 7. (a) Particle size distribution and (b) SEM image of the nanoparticles stored at 25 ◦C for 7 days.
3.4. In Vitro Drug Release Studies
The drug release studies of DNP formulation were performed under pH 7.4 for 72 h. It was
observed that th fir t burst release of the dr g occurr d in the first 8 h of incubation period. It can
Polymers 2020, 12, 1798 12 of 17
be seen that there was a time-dependent exponential increase in the drug release for 24 h. This was
followed by sustained release of drug from DNP as shown in Figure 8. This study clearly shows that
we may expect to see the desired pharmacological activity within 24 to 48 h.
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3.5. In Vitro Cytotoxicity Studies
To evaluate the anticancer therapeutic efficacy of synthesized DNPs, cytotoxicity studies were
performed on cancer cell lines such as MIA PaCa-2 and MCF-7. We also checked the effect of DNPs on
normal mice fibroblast (L929) cell line. Both, BSA NP treatment for MCF-7, MIA PaCA-2, L929 and
DNP against L929 were taken as −ve controls for the analysis. In addition, native drug treated MCF-7,
MIA PaCa-2 and L929 were taken as +ve control for the cytotoxicity assay (Figure 10). The cytotoxicity
for all the test and −ve control group was recorded at 24 and 48 h intervals as shown in Figure 9.
We were able to see a concentration dependent cytotoxicity for DNPs towards MIA PaCa-2 and
MCF-7 cell line in comparison to L929 as shown in Figure 9a,b (with p < 0.05). Moreover, a similarity
in the therapeutic efficacy of DNPs formulation towards MIA PaCa-2 and MCF-7 cell lines for all
the concentrations (0.1 to 1 mg/mL) was also observed, as shown in Figure 9a,b. At, 24 and 48 h of
incubation for all the three cell lines, DNPs exhibited relatively high cytotoxicity towards cancer cell
lines (MIA PaCa-2 and MCF-7) compared to normal L929 cell line.
Moreover, it was also observed that for MIA PaCa-2 and MCF-7 cell lines, DNPs shows good cell
growth inhibition at 1 mg/mL concentration in 24 h and 48 h intervals (p < 0.05) as shown in Figure 9.
After 24 h of incubation we observed that DNPs at 1 mg/mL concentration, the percentage of cell
viability for MIA PaCa-2 and MCF-7 cells were found to be around 62% and 63%, respectively. After 48 h,
the viability further dropped to around 53% and 52% for MIA PaCa-2 and MCF-7, respectively. A similar
variation in percentage of cell viability of MIA PaCa-2 and MCF-7 was seen for other concentrations of
DNPs (with p < 0.05) as shown in Figure 9. Our results clearly shows selective cancer killing by DNPs
due to the presence of Hsp90 inhibitor (luminespib) in them [22]. In comparison to standard free drug
(luminespib), DNPs formulations were shown to have controlled and sustained cytotoxic (over 24 and
48 h) effect in comparison to free drug (Figure 10) for all the three concentrations against all the three
cell lines.
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manner towards MiaPaCa-2, MCF-7 and L929 cell lines. The study shows statistical significance of *, **,
*** p < 0.05 within various groups marked in figure. The student t test carried out by comparing the
lower concentration (100 µg/mL) treated group with high concentration (500 and 1000 µg/mL) treated
group for each cell line.
4. Conclusions
We have developed luminespib-loaded BSA NPs (DNPs) for breast and pancreatic cancer therapy
that can be dispensed in an aqueous vehicle. Our fluorescence quenching experiments show that
luminespib interacts with BSA and forms nanoparticles by classical desolvation method. Our docking
study predicted that the probable binding site of the luminespib in BSA during formation of DNPs
with l west Gibbs free energy of bind ng of rug-BSA complex is around hydrophilic domain I of BSA.
Our cellular biocompatibility studies lso demonstrate the safety profi e in a ncentration-dep ndent
manner for DNPs and native BSA NPs in normal L929 cell line in comparison to cancer cell lines such
as MIA PaCa-2 and MCF-7. We also observed significant (p < 0.05) anticancer effect for our DNPs in
comparison to native BSA NPs. We believe that this difference is due to non-covalent conjugation of
drug in DNPs in comparison to native BSA NPs. We found that the anticancer efficacy of our DNP
formulation was similar for MIA PaCa-2 and MCF-7 cell lines. We believe that this work can be the
first step in the direction of improving the formulation Hsp90 inhibitors by using natural biomaterials
like BSA.
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